When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

MannKind

The Trade: MannKind Corporation (NASDAQ:MNKD) CEO Michael Castagna acquired a total of 5000 shares shares at an average price of $2.99. The insider spent $14,950.00 to buy those shares.

What’s Happening: MannKind was granted U.S. patent titled 'Apparatus and method for cryogranulating a pharmaceutical composition.'

What MannKind Does: MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

Pixelworks

The Trade: Pixelworks, Inc. (NASDAQ:PXLW) VP and CFO Elias Nader acquired a total of 3000 shares at an average price of $2.56. To acquire these shares, it cost $7,675.50.

What’s Happening: Pixelworks is expected to report results for the second quarter on August 10, 2021.

What Pixelworks Does: Pixelworks is a part of the technology sector in the United States. It provides high-performance and power-efficient visual processing solutions.

Emmaus Life Sciences

The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Chairman and CEO Yutaka Niihara acquired a total of 4100 shares shares at an average price of $1.48. The insider spent $6,072.00 to buy those shares.

What’s Happening: Emmaus Life Sciences, last month, reported preliminary sales results for the six months ended June 30, 2021.

What Emmaus Life Sciences Does: Emmaus Life Sciences is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases.